Sorry, you need to enable JavaScript to visit this website.
Dexcom G7 is now covered by ODB for patients living with diabetes on insulin*

The #1 preferred glucose sensor by Canadian endocrinologists†,1 is now the most covered CGM on government funded programs in Ontario for people on insulin.*,2 

Image
Dexcom G7 user checking their glucose levels.

Dexcom G7 is easy to use and prescribe 

It’s covered by ODB and most private insurers for patients on insulin in Ontario. Write a prescription and your patient is set, no prior approval, LU codes, or forms are needed through ODB.

Prescribe the right CGM for your patients

Image
Accuracy Icon

The most accurate CGM with clinically proven outcomes‡,2

Clinically proven to lower A1C, reduce hypoglycemic events, increase time in range, and improve glycemic outcomes.3-7 

Image
Urgent Low Icon

Alerts that support safer insulin therapy

The predictive "Urgent Low Soon" alert can warn patients in advance of severe hypoglycemia§, plus the Delay 1st High alert after a meal may help reduce insulin stacking.8,9

Image
Easy Icon

Unparalleled convenience for any lifestyle

The only waterproof CGM that has the fastest warm-up time, multiple wear locations# and display devices. 

Request a Dexcom G7 sample

It's easy to introduce your diabetes patients to the power of Dexcom rtCGM with a FREE 10-day sample. Patients must have a compatible smart device (sold separately): dexcom.com/compatibility.
 
Fields marked with an * are required. You may choose to provide the optional information to help us assign the appropriate representative to assist you with your inquiry.
 
 

A response will not be provided for inquiries from outside of Canada.

Please see dexcom.com for information on our consumer products.
*Stay up-to-date with Dexcom
Would you like to stay up-to-date with Dexcom products, educational events and news via email?
By choosing to opt-in, you are granting DexCom, Inc. and Dexcom Canada, Co. (together "Dexcom")permission to process the personal data you have provided so that we may send you additional information and communications by email related to Dexcom products from time-to-time. You may opt-out of these solicitations at any time by selecting the unsubscribe link at the bottom of any email or by contacting us by email at [email protected] or by mail at the address listed in Contact Us, and you may opt-in again through one of those contacts. Dexcom respects the privacy and confidentiality of your personal information. We will not share your personal information with any third-parties, except as otherwise noted in our Privacy Policy.
LBL-1004197 Rev001

Resources to help you get to know Dexcom G7 a bit better

* For ODB eligible persons who are on insulin therapy for diabetes and who have a valid prescription for Dexcom G7 from a physician or nurse practitioner. Limit of 45 Dexcom G7 Sensors per eligible person per 365-day period. Dexcom G7 Receivers are also covered if there is no compatible smart device. For detailed coverage criteria, please visit https://www.dexcom.com/en-CA/coverage/ontario-provincial-cgm-coverage. 
† Based on a survey of Canadian Endocrinologists (n=41)    
‡ When compared with CGM systems commercially available in Canada as of July 2025. Sensors worn on the back of the upper arm have been found to be slightly more accurate than sensors worn on the abdomen. 
§ Audible and visual notification of predictive alert at 3.1 mmol/L within 20 minutes. For more information, review the Dexcom G7 User Guide.  
¶ The Dexcom G7 Sensor is waterproof and may be submerged under eight feet of water for up to 24 hours without failure when properly installed. 
# Indicated for wear on the back of the upper arm and abdomen for ages 2 years and older or the upper buttocks for ages 2-6 years old. 
** Smart devices sold separately. For a list of compatible devices, please visit dexcom.com/compatibility.

1 dQ&A, Dexcom Canadian Endos Report Wave 1 2024
2 Dexcom data on file, 2025
3 Beck, RW, et al. JAMA. 2017;317(4):371-378.  
4 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.  
5 Martens T, et al. JAMA. 2021;325(22):2262-2272.  
6 Laffel LM, et al. JAMA. 2020;323(23):2388-2396.  
7 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7. 
8 Aly A, et al. Diabetes Technol. Ther. 2024;26(S2): A254-255.  
9 Puhr S, et al. Diabetes Technol Ther. 2019;21(4):155-158.